Lynparza delays disease progression in phase III trial for ovarian cancer

This article was originally published here

AstraZeneca and Merck have announced positive results from the randomised, double-blinded, placebo-controlled, Phase III SOLO-1 trial of Lynparza (olaparib) tablets.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply